Table 3.

Cox regression analysis of outcomes in patients with AMI.

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value
ePVS > 5.5%	3.116 (2.311–4.202)	<0.001	1.879 (1.343–2.629)	<0.001
Age	1.092 (1.074–1.109)	<0.001	1.077 (1.059–1.095)	<0.001
Male sex	0.931 (0.662–1.308)	0.680	1.678 (1.132–2.487)	0.010
Killip III or IV classification	2.680 (1.838–3.908)	<0.001	1.739 (1.151–2.627)	0.009
Hypertension	1.091 (0.798–1.492)	0.586	0.894 (0.639–1.249)	0.510
Dyslipidaemia	0.504 (0.373–0.682)	<0.001	0.715 (0.519–0.984)	0.039
Diabetes mellitus	1.158 (0.858–1.564)	0.337	1.049 (0.765–1.439)	0.765
Smoking	0.701 (0.511–0.961)	0.027	1.243 (0.874–1.767)	0.226
Atrial fibrillation	2.586 (1.604–4.168)	<0.001	1.431 (0.847–2.417)	0.181
Peripheral artery disease	1.450 (0.595–3.537)	0.414	0.857 (0.339–2.168)	0.745
History of myocardial infarction	1.661 (0.994–2.777)	0.053	0.981 (0.557–1.727)	0.946
History of stroke	2.362 (1.576–3.539)	<0.001	1.194 (0.776–1.838)	0.420
Multivessel disease	1.153 (0.844–1.575)	0.370	1.069 (0.773–1.479)	0.686
LVEF at discharge	0.954 (0.942–0.966)	<0.001	0.967 (0.953–0.981)	<0.001
eGFR	0.981 (0.975–0.988)	<0.001	1.00 (0.990–1.005)	0.569
ACEis or ARBs or ARNIs	0.401 (0.237–0.681)	<0.001	0.714 (0.405–1.259)	0.245
Beta‐blockers	0.650 (0.466–0.907)	0.011	0.717 (0.507–1.015)	0.061
Aldosterone antagonists	1.662 (1.148–2.404)	0.007	0.838 (0.564–1.245)	0.382
Statins	0.340 (0.247–0.468)	<0.001	0.654 (0.460–0.929)	0.018

Abbreviations ACEis, angiotensin‐converting enzyme inhibitors; AMI, acute myocardial infarction; ARBs, angiotensin II receptor blockers; ARNIs, angiotensin receptor neprilysin inhibitors; CI, confidence interval; eGFR, estimated glomerular filtration rate; ePVS, estimated plasma volume status; HR, hazard ratio; LVEF, left ventricular ejection fraction.